General Information of Drug Therapeutic Target (DTT) (ID: TTPH7T0)

DTT Name Tumor expressed melanoma antigen (PRAME)
Synonyms Preferentially expressed antigen of melanoma; Opa-interacting protein 4; OIP-4; Melanoma antigen preferentially expressed in tumors; MAPE
Gene Name PRAME
DTT Type
Clinical trial target
[1]
UniProt ID
PRAME_HUMAN
TTD ID
T03189
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MERRRLWGSIQSRYISMSVWTSPRRLVELAGQSLLKDEALAIAALELLPRELFPPLFMAA
FDGRHSQTLKAMVQAWPFTCLPLGVLMKGQHLHLETFKAVLDGLDVLLAQEVRPRRWKLQ
VLDLRKNSHQDFWTVWSGNRASLYSFPEPEAAQPMTKKRKVDGLSTEAEQPFIPVEVLVD
LFLKEGACDELFSYLIEKVKRKKNVLRLCCKKLKIFAMPMQDIKMILKMVQLDSIEDLEV
TCTWKLPTLAKFSPYLGQMINLRRLLLSHIHASSYISPEKEEQYIAQFTSQFLSLQCLQA
LYVDSLFFLRGRLDQLLRHVMNPLETLSITNCRLSEGDVMHLSQSPSVSQLSVLSLSGVM
LTDVSPEPLQALLERASATLQDLVFDECGITDDQLLALLPSLSHCSQLTTLSFYGNSISI
SALQSLLQHLIGLSNLTHVLYPVPLESYEDIHGTLHLERLAYLHARLRELLCELGRPSMV
WLSANPCPHCGDRTFYDPEPILCPCFMPN
Function
Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG. Prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis.

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
IMC-F106C DMHQ2U8 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
IMA 203 DMD9U5Q Hematologic tumour 2B33.Y Phase 1 [3]
------------------------------------------------------------------------------------

References

1 Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells. Cancer Lett. 2017 Sep 10;403:144-151.
2 Clinical pipeline report, company report or official report of Immunocore.
3 Clinical pipeline report, company report or official report of Immatics.